Macrogenics Inc (NASDAQ: MGNX) on Friday, plunged -5.00% from the previous trading day, before settling in for the closing price of $2.10. Within the past 52 weeks, MGNX’s price has moved between $2.03 and $19.54.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 45.47% over the past five years. The company achieved an average annual earnings per share of -135.20%. With a float of $57.70 million, this company’s outstanding shares have now reached $62.82 million.
Let’s look at the performance matrix of the company that is accounted for 341 employees. In terms of profitability, gross margin is 89.25%, operating margin of -74.54%, and the pretax margin is -44.51%.
Macrogenics Inc (MGNX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Macrogenics Inc is 8.07%, while institutional ownership is 84.48%. The most recent insider transaction that took place on Feb 15 ’25, was worth 1,083. In this transaction VP, Controller & Treasurer of this company sold 423 shares at a rate of $2.56, taking the stock ownership to the 9,532 shares. Before that another transaction happened on Apr 04 ’24, when Company’s Senior VP and General Counsel sold 51,395 for $15.55, making the entire transaction worth $799,148. This insider now owns 0 shares in total.
Macrogenics Inc (MGNX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -135.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -28.62% during the next five years compared to 19.47% growth over the previous five years of trading.
Macrogenics Inc (NASDAQ: MGNX) Trading Performance Indicators
Macrogenics Inc (MGNX) is currently performing well based on its current performance indicators. A quick ratio of 3.92 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.07, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of Macrogenics Inc (MGNX)
Macrogenics Inc (NASDAQ: MGNX) saw its 5-day average volume 0.57 million, a negative change from its year-to-date volume of 0.62 million. As of the previous 9 days, the stock’s Stochastic %D was 22.00%. Additionally, its Average True Range was 0.17.
During the past 100 days, Macrogenics Inc’s (MGNX) raw stochastic average was set at 3.27%, which indicates a significant decrease from 17.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.21% in the past 14 days, which was higher than the 63.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.6750, while its 200-day Moving Average is $3.5375. Nevertheless, the first resistance level for the watch stands at $2.1533 in the near term. At $2.3117, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.4433. If the price goes on to break the first support level at $1.8633, it is likely to go to the next support level at $1.7317. The third support level lies at $1.5733 if the price breaches the second support level.
Macrogenics Inc (NASDAQ: MGNX) Key Stats
Market capitalization of the company is 125.21 million based on 62,763K outstanding shares. Right now, sales total 58,750 K and income totals -9,060 K. The company made 110,710 K in profit during its latest quarter, and 56,310 K in sales during its previous quarter.
